REBBECCA OLIVER: Open Payments
NPI 1043903750 · LIVINGSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 35 payments from 13 companies in 2025. Trend: 2023 $129 · 2024 $626 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $112 |
| HARMONY BIOSCIENCES LLC | 3 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $98 |
| ABBVIE INC. | 5 | $93 |
| AstraZeneca Pharmaceuticals LP | 3 | $73 |
| Lilly USA, LLC | 3 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Antares Pharma, Inc. | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| CeQur Corporation | 1 | $33 |
Products named: WAKIX, CAPLYTA, QULIPTA, AIRSUPRA, XIFAXAN, XYOSTED, Ozempic, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
